<DOC>
	<DOCNO>NCT00703469</DOCNO>
	<brief_summary>This study examine safety , tolerability , immunogenicity single dose MDX-1106 patient active hepatitis C genotype 1 mixed hepatitis C genotype infection .</brief_summary>
	<brief_title>A Study MDX-1106 Treat Patients With Hepatitis C Infection</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Infection hepatitis C genotype 1 mixed hepatitis C genotype ; Asymptomatic nearly asymptomatic hepatitis C ; Previous therapy interferon ribavirin peginterferon ribavirin without SVR relapse follow SVR ; Interferon naive subject Chronically infect ( least 6 month since diagnosis ) HCVpositive subject ; No evidence bridge necrosis cirrhosis ; Liver biopsy within last 2 year Acute hepatitis C infection History prior malignancy , acquire inherited immunodeficiency autoimmune disease either document anecdotal ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Hep C</keyword>
</DOC>